RAPT Gross Profit from 2010 to 2025

RAPT Stock

USD 1.31 0.11 9.17%

RAPT Therapeutics Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit RAPT Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

-3.2 M

Current Value

-3 M

Quarterly Volatility

2.3 M

Credit Downgrade

Yuan Drop

Covid

Check RAPT Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RAPT Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 952.3 K, Interest Expense of 1.3 M or Selling General Administrative of 16.7 M, as well as many indicators such as Price To Sales Ratio of 208, Dividend Yield of 0.0 or PTB Ratio of 0.32. RAPT financial statements analysis is a perfect complement when working with RAPT Therapeutics Valuation or Volatility modules.

Check out the analysis of RAPT Therapeutics Correlation against competitors.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

Latest RAPT Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of RAPT Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of RAPT Therapeutics minus its cost of goods sold. It is profit before RAPT Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. RAPT Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in RAPT Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.53 M

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

RAPT Gross Profit Regression Statistics

	Arithmetic Mean	(793,813)
	Coefficient Of Variation	(294.43)
	Mean Deviation	1,595,430
	Median	(1,330,000)
	Standard Deviation	2,337,243
	Sample Variance	5.5T
	Range	8.6M
	R-Value	0.06
	Mean Square Error	5.8T
	R-Squared	0
	Significance	0.83
	Slope	28,375
	Total Sum of Squares	81.9T

RAPT Gross Profit History

	2025	-3 M
	2024	-3.2 M
	2023	-3.6 M
	2022	1.5 M
	2021	3.8 M
	2020	5 M

Other Fundumenentals of RAPT Therapeutics

Gross Profit Margin

RAPT Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Capital Stock	Current Deferred Revenue	Short Term Debt	Short Term Investments	Deferred Long Term Liab
Total Assets		0.95	0.93	-0.32	-0.86	0.62	0.93	-0.68	0.95	1.0	0.99	0.63	0.23	0.56	-0.92	0.1	0.62	-0.84
Total Stockholder Equity	0.95		0.9	-0.28	-0.82	0.66	0.9	-0.87	1.0	0.95	0.95	0.57	0.5	0.48	-0.84	0.17	0.59	-0.76
Net Tangible Assets	0.93	0.9		-0.46	-0.95	0.66	1.0	-0.69	0.9	0.93	0.91	0.75	0.2	0.69	-0.92	-0.03	0.45	-0.91
Net Debt	-0.32	-0.28	-0.46		0.65	0.1	-0.5	0.18	-0.28	-0.33	-0.25	-0.91	-0.06	-0.92	0.41	0.55	0.36	0.67
Retained Earnings	-0.86	-0.82	-0.95	0.65		-0.61	-0.97	0.6	-0.82	-0.86	-0.82	-0.87	-0.16	-0.83	0.91	0.26	-0.25	0.96
Accounts Payable	0.62	0.66	0.66	0.1	-0.61		0.67	-0.59	0.66	0.6	0.62	0.2	0.25	0.13	-0.65	-0.08	0.52	-0.5
Capital Surpluse	0.93	0.9	1.0	-0.5	-0.97	0.67		-0.69	0.9	0.93	0.91	0.78	0.21	0.72	-0.93	-0.06	0.44	-0.93
Total Liab	-0.68	-0.87	-0.69	0.18	0.6	-0.59	-0.69		-0.87	-0.67	-0.68	-0.4	-0.83	-0.29	0.56	-0.24	-0.42	0.51
Net Invested Capital	0.95	1.0	0.9	-0.28	-0.82	0.66	0.9	-0.87		0.95	0.95	0.57	0.5	0.48	-0.84	0.17	0.59	-0.76
Total Current Assets	1.0	0.95	0.93	-0.33	-0.86	0.6	0.93	-0.67	0.95		0.99	0.63	0.22	0.57	-0.92	0.11	0.61	-0.84
Net Working Capital	0.99	0.95	0.91	-0.25	-0.82	0.62	0.91	-0.68	0.95	0.99		0.57	0.23	0.51	-0.91	0.19	0.7	-0.81
Common Stock	0.63	0.57	0.75	-0.91	-0.87	0.2	0.78	-0.4	0.57	0.63	0.57		0.07	0.99	-0.71	-0.33	-0.05	-0.89
Property Plant Equipment	0.23	0.5	0.2	-0.06	-0.16	0.25	0.21	-0.83	0.5	0.22	0.23	0.07		-0.03	-0.08	0.18	0.12	-0.05
Capital Stock	0.56	0.48	0.69	-0.92	-0.83	0.13	0.72	-0.29	0.48	0.57	0.51	0.99	-0.03		-0.66	-0.37	-0.11	-0.87
Current Deferred Revenue	-0.92	-0.84	-0.92	0.41	0.91	-0.65	-0.93	0.56	-0.84	-0.92	-0.91	-0.71	-0.08	-0.66		0.02	-0.55	0.94
Short Term Debt	0.1	0.17	-0.03	0.55	0.26	-0.08	-0.06	-0.24	0.17	0.11	0.19	-0.33	0.18	-0.37	0.02		0.54	0.16
Short Term Investments	0.62	0.59	0.45	0.36	-0.25	0.52	0.44	-0.42	0.59	0.61	0.7	-0.05	0.12	-0.11	-0.55	0.54		-0.33
Deferred Long Term Liab	-0.84	-0.76	-0.91	0.67	0.96	-0.5	-0.93	0.51	-0.76	-0.84	-0.81	-0.89	-0.05	-0.87	0.94	0.16	-0.33

Click cells to compare fundamentals

About RAPT Therapeutics Financial Statements

RAPT Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although RAPT Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in RAPT Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on RAPT Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	-3.2 M	-3 M
Gross Profit Margin	(0.96)	(0.92)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC